Finola Moore, PhD

Finola Moore, PhD, Director, Pipeline Research

Finola joined Catamaran as Director, Pipeline Research in May 2021. Prior to Catamaran, Finola was Director of Program Management, Research, at Arbor Biotechnologies, where she managed the collaboration with Vertex Pharmaceuticals focused on innovative programs in gene therapy, including the development of novel CRISPR nucleases for therapeutic gene editing. Before Arbor, Finola was Associate Director of Immune Tolerance at SQZ Biotechnologies, where she led the cell therapy project to modulate the immune system for the treatment of autoimmune disease. This project at SQZ received awards from private foundations and grants, and Finola won a Women in the Enterprise of Science and Technology award during this time. Finola conducted her postdoctoral training at Massachusetts General Hospital/Harvard Medical School with a focus on stem cells in cancer for their role in leukemia relapse. Finola holds a PhD in Molecular Pharmacology and Biological Chemistry from Northwestern University and a BS in Biology and Genetics from McGill University.